{"id":"grass-pollen-formulation","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (itching, swelling, erythema)"},{"rate":null,"effect":"Oral pruritus"},{"rate":null,"effect":"Mild systemic allergic reactions"},{"rate":null,"effect":"Anaphylaxis (rare)"}]},"_chembl":{"chemblId":"CHEMBL2109011","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This immunotherapy formulation contains grass pollen allergens that are administered in gradually increasing doses to induce immune tolerance. Over time, this process shifts the immune response from IgE-mediated (allergic) to IgG-mediated (protective) antibodies and increases regulatory T cells, reducing allergic symptoms upon natural grass pollen exposure.","oneSentence":"A grass pollen allergen extract that desensitizes the immune system to grass pollen allergens through repeated controlled exposure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:16.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Grass pollen-induced allergic rhinitis"},{"name":"Grass pollen-induced allergic asthma"}]},"trialDetails":[{"nctId":"NCT02975479","phase":"PHASE2, PHASE3","title":"Intralymphatic Immunotherapy in Increasing Doses, Substudy","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2016-05","conditions":"Rhinitis, Allergic, Seasonal","enrollment":40},{"nctId":"NCT02423707","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-08","conditions":"Allergic Rhinitis","enrollment":110},{"nctId":"NCT00264459","phase":"PHASE3","title":"Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2003-02","conditions":"Grass Pollen Allergy","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["specific immunotherapy"],"phase":"phase_3","status":"active","brandName":"Grass pollen formulation","genericName":"Grass pollen formulation","companyName":"Allergopharma GmbH & Co. KG","companyId":"allergopharma-gmbh-co-kg","modality":"Biologic","firstApprovalDate":"","aiSummary":"A grass pollen allergen extract that desensitizes the immune system to grass pollen allergens through repeated controlled exposure. Used for Grass pollen-induced allergic rhinitis, Grass pollen-induced allergic asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}